For more than a century, photographers have had to choose which part of a scene should be tack sharp and which parts would ...

Discover why Schwab U.S. Dividend Equity ETF's dividend growth is lagging, the impact of recent rebalancing, and if now’s the ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...

– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today ...

Researchers at Karolinska Institutet and KTH have developed a computational method that can reveal how cells change and specialize in the body. The study, which has been published in the journal PNAS, ...

Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

Landlords could no longer rely on rent-pricing software to quietly track each other's moves and push rents higher using confidential data, under a settlement between RealPage Inc. and federal ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...

Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically ...

– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...